B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) is an indication for drug development with over 210 pipeline drugs currently active. According to GlobalData, preregistered drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) compared to historical benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) overview

B-cell acute lymphocytic leukemia (B-Cell ALL), also known as B-cell acute lymphoblastic leukemia, is a type of blood cancer that originates in the bone marrow and affects B-cell lymphocytes, a type of white blood cell. In B-cell ALL, these immature B cells undergo malignant transformation, leading to the rapid production of abnormal lymphoblasts. These abnormal cells can crowd out normal blood cells, leading to symptoms such as fatigue, anemia, increased susceptibility to infections, and bleeding. B-cell ALL is most commonly diagnosed in children but can affect adults as well. Treatment typically includes chemotherapy, targeted therapies, stem cell transplantation, and sometimes radiation therapy. The goal is to induce remission and eliminate cancer cells from the bone marrow. Advances in treatment have improved the prognosis for many patients with B-cell ALL.

For a complete picture of PTSR and LoA scores for drugs in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.